Filter posts

BIO Mourns Passing of Dr. John Holaday

On behalf of the team at BIO, we send our deepest condolences to the family …

#TBT: Debunking Some Common Myths on Patent Protections

The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is …

The Challenges and Risks of Adopting Foreign Price Controls

The Trump Administration is moving forward with a plan to import foreign price controls into …

As Mosquito Fears Rise, EPA Considers Oxitec 2nd Generation Trial

Most people consider mosquitoes to be a summertime pest – the unwelcome guest at the …

ICYMI: Biopharmaceutical Companies Aren’t Free-Riding on Government Research

Writing for the Boston Globe, Dr. Michael Rosenblatt, chief medical officer of the venture firm …

Discrimination Against Vulnerable Patients Is Nothing New

Transformative therapies are advancing like never before, and a new class of medicines are changing …

National Immunization Awareness Month Is a Reminder About the Value of Vaccines

Writing for Morning Consult, Dr. Judy Monroe, president and CEO of the CDC Foundation, highlights …

The BIO Investor Forum Links Promising Early-Stage Technologies with an Active Investor Network

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial …

New Coalition to Raise Awareness of Antimicrobial Resistance Threat, Call for Urgent Solutions

The Biotechnology Innovation Organization (BIO), leading scientists, public policy experts, and industry leaders today announced …

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest …